Fractyl Health

Historical price data

Fractyl Health is on a mission to break the pattern of chronic drug therapy for obesity and type 2 diabetes by developing durable, disease-modifying treatments. The company's two core platforms target key metabolic organs: Revita addresses duodenal dysfunction via an outpatient endoscopic procedure, while Rejuva is a novel AAV gene therapy targeting pancreatic islet cells. Fractyl is publicly traded (NASDAQ: GUTS) and is advancing its pivotal REMAIN-1 study for Revita, positioning it at the intersection of the massive obesity and diabetes markets with a focus on long-term solutions beyond chronic pharmacotherapy.

Two core platforms: 1) Revita, an endoscopic hydrothermal ablation system designed to durably remodel the duodenal lining to restore metabolic health; 2) Rejuva, a locally administered AAV gene therapy platform designed to reprogram pancreatic islet cells for durable treatment of obesity and diabetes.

Competes with chronic GLP-1 drug manufacturers (Novo Nordisk, Eli Lilly), bariatric surgery, and other metabolic device companies. Key differentiation is the focus on one-time, durable, organ-targeted therapies aimed at the root cause of disease, rather than chronic systemic treatment.